Novo Nordisk vs. Mylan: GLP-1 Patent Dispute Dismissed Without Prejudice
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novo Nordisk A/S v. Mylan Pharmaceuticals Inc. |
| Case Number | 1:24-cv-00050 (D. Del.) |
| Court | District of Delaware |
| Duration | Jan 2024 – Mar 2025 1 year 2 months |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | GLP-1 Compositions |
Case Overview
The Parties
⚖️ Plaintiff
Danish multinational pharmaceutical company, global leader in diabetes and obesity care, with a dominant commercial position in GLP-1 receptor agonist therapies.
🛡️ Defendant
Leading generic drug manufacturer with an extensive history of ANDA filings and Paragraph IV certifications challenging branded pharmaceutical patents.
Patents at Issue
This litigation centered on U.S. Patent No. 11,752,198 (“the ‘198 Patent”), covering GLP-1 compositions and uses thereof. A related case also saw claims involving U.S. Patent No. 10,888,605 dismissed.
- • US 11,752,198 — GLP-1 compositions and their therapeutic uses
- • US 10,888,605 — (Related case patent, dismissed simultaneously)
Developing a similar GLP-1 product?
Check if your GLP-1 composition might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On March 21, 2025, the parties filed a **Joint Stipulation of Dismissal Without Prejudice** pursuant to Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c). The Court approved the stipulation and closed the docket. No damages were awarded, and no injunctive relief was granted or denied. The dismissal without prejudice expressly preserves both parties’ rights to re-litigate these claims in the future.
Key Legal Issues
The stipulated dismissal does not reflect a judicial determination on the merits of infringement, validity, or claim construction. The “without prejudice” designation is legally significant: Novo Nordisk retains the right to re-file infringement claims based on the ‘198 Patent if Mylan’s product progresses toward market entry or if claim scope is later confirmed to cover Mylan’s formulation.
Developing a new GLP-1 patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for GLP-1 Compositions
This case highlights critical IP risks in the GLP-1 pharmaceutical space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related GLP-1 patents in this technology space
- See which companies are most active in GLP-1 IP
- Understand claim construction patterns for GLP-1
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your GLP-1 technology or product.
- Input your product description or technical features
- AI identifies potentially blocking GLP-1 patents
- Get actionable risk assessment report
High Risk Area
GLP-1 Compositions
2 Patents at Issue
(Including related case, C.A. No. 23-101-CFC)
Unresolved Claim Scope
For the ‘198 Patent
✅ Key Takeaways
For Patent Attorneys & Litigators
Dismissals without prejudice in ANDA cases preserve future assertion rights — a critical drafting consideration in any stipulation.
Search related case law →Coordinated multi-patent, multi-case dismissals suggest overarching strategic frameworks beyond individual case management.
Explore precedents →The ‘198 Patent remains enforceable and unlitigated on the merits — watch for future assertions.
View ‘198 Patent details →For R&D Leaders
Updated FTO analysis for GLP-1 composition development is essential given the ‘198 Patent’s unresolved scope.
Start FTO analysis for my product →Track C.A. No. 23-101-CFC developments for related ‘605 Patent status.
View ‘605 Patent details →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.